Avalon's Sweat Equity
This article was originally published in Start Up
Avalon Ventures closed its ninth fund in January with $200 million committed, $50 million more than planned and a third larger than its previous fund. For a firm that invests half its money in tiny lifescience start-ups, it was an impressive number at a time when the venture industry is reeling. That’s a vote of confidence in the firm’s unusual "sweat equity" strategy.
You may also be interested in...
Entering its fourth decade, Avalon fights through “dark days” and taps GlaxoSmithKline to help fund its next crop of early-stage start-ups. In exchange, it must deliver assets, not platforms, to trigger a GSK acquisition of those start-ups, with pre-arranged returns.
Our survey of news from the first day of BIO 2013 includes a look at Bayer’s business development plans, Avalon Ventures’ tie-up with GlaxoSmithKline, and news from panel discussions on orphan drugs, venture philanthropy and Russia.
Avalon-backed RQx will team with Genentech to discover and develop antibiotics against a novel, undisclosed target. The deal essentially is an exit for hybrid VC firm Avalon, which already has exit deals this year with BioMarin and Genentech.